Drugs. 2008;68(11):1543-69.

Irbesartan: a review of its use in hypertension and diabetic nephropathy.

Source

Wolters Kluwer Health | Adis, Auckland, New Zealand.

Abstract

Irbesartan (Aprovel, Avapro, Irbetan, Karvea), an angiotensin II receptor type 1 antagonist, is approved in many countries worldwide for the treatment of hypertension. It is also approved in some regions for the treatment of nephropathy in patients with hypertension and type 2 diabetes mellitus. In adults with essential hypertension, irbesartan is effective at reducing blood pressure (BP) over a 24-hour period with once-daily administration. Irbesartan also slows the progression of renal disease in hypertensive patients with type 2 diabetes, with this effect partly independent of its BP-lowering effect. In addition, irbesartan was generally well tolerated in clinical trials. Thus, irbesartan is a useful treatment option for patients with hypertension, including those with type 2 diabetes and nephropathy.

PMID:: 18627212; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Angiotensin receptors - Guide to Pharmacology

Supplemental Content

Save items

Related citations in PubMed

Review Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. [Drugs. 2004]
Review Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
Croom KF, Curran MP, Goa KL, Perry CM. Drugs. 2004; 64(9):999-1028.
Review Treatment of diabetic nephropathy with angiotensin II receptor antagonist. [Clin Exp Nephrol. 2003]
Review Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ, Lewis JB. Clin Exp Nephrol. 2003 Mar; 7(1):1-8.
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension. [Curr Med Res Opin. 2006]
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Palmer AJ, Valentine WJ, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, et al. Curr Med Res Opin. 2006 Nov; 22(11):2095-100.
Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective. [Clin Ther. 2007]
Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.
Coyle D, Rodby R, Soroka S, Levin A, Muirhead N, de Cotret PR, Chen R, Palmer A. Clin Ther. 2007 Jul; 29(7):1508-23.
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. [N Engl J Med. 2001]
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, et al. N Engl J Med. 2001 Sep 20; 345(12):851-60.

See reviews... See all...

Cited by 2 PubMed Central articles

Long-term use and tolerability of irbesartan for control of hypertension. [Integr Blood Press Control. 2011]
Long-term use and tolerability of irbesartan for control of hypertension.
Forni V, Wuerzner G, Pruijm M, Burnier M. Integr Blood Press Control. 2011; 4:17-26. Epub 2011 Apr 18.
Angiotensin II mediates the high-glucose-induced endothelial-to-mesenchymal transition in human aortic endothelial cells. [Cardiovasc Diabetol. 2010]
Angiotensin II mediates the high-glucose-induced endothelial-to-mesenchymal transition in human aortic endothelial cells.
Tang R, Li Q, Lv L, Dai H, Zheng M, Ma K, Liu B. Cardiovasc Diabetol. 2010 Jul 27; 9:31. Epub 2010 Jul 27.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Irbesartan: a review of its use in hypertension and diabetic nephropathy.
Irbesartan: a review of its use in hypertension and diabetic nephropathy.
Drugs. 2008 ;68(11):1543-69.

PubMed
Cell-based influenza vaccines: progress to date.
Cell-based influenza vaccines: progress to date.
Drugs. 2008 ;68(11):1483-91.

PubMed
Novel thermoresponsive nonviral gene vector: P(NIPAAm-co-NDAPM)-b-PEI with adjus...
Novel thermoresponsive nonviral gene vector: P(NIPAAm-co-NDAPM)-b-PEI with adjustable gene transfection efficiency.
Bioconjug Chem. 2008 Jul ;19(7):1368-74.

PubMed
Three-dimensional study of the musculotendinous architecture of lumbar multifidu...
Three-dimensional study of the musculotendinous architecture of lumbar multifidus and its functional implications.
Clin Anat. 2008 Sep ;21(6):539-46.

PubMed
Mechanisms of imprinting of the Prader-Willi/Angelman region.
Mechanisms of imprinting of the Prader-Willi/Angelman region.
Am J Med Genet A. 2008 Aug 15 ;146A(16):2041-52.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Irbesartan: a review of its use in hypertension and diabetic nephropathy.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 2 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information